WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company will participate at the following upcoming investor conferences in November 2026:
Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026Announced positive results from
Conference Call and Webcast to FollowWASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October
Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpointConsistent with prior studies, VQW-765 was safe and well toleratedWASHINGTON, Oct. 14, 2026 /PRNewswire/ --
WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna,
Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022)60% of HETLIOZ® treated participants shifted sleep at least 30 minutes earlier, compared to 15% of the placebo
WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company will participate at the following upcoming investor conferences in September 2026:
WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete
Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% Full-year 2026 total revenue guidance of $240-$290 million Cash totaled $170.0 million as of June 30, 2026; expected to
Conference Call and Webcast to FollowWASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5,
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit
